Mechanism · Research Data · Stack Rationale · Compound Information
RU58841 and GHK-Cu are discussed together because they target different parts of the hair-loss theory: androgen signalling and the surrounding tissue environment. Each compound has separate preclinical research, but the pair has not been tested together in a dedicated clinical trial. RU58841 does not have large-scale human hair-loss trials, and the page itself notes an evidence gap around direct GHK-Cu hair-follicle claims. This is a mechanism-based research idea, not a validated treatment protocol.
Hair health research around androgenetic alopecia generally splits into two separate problems: the hormonal driver and the tissue environment. RU58841 is studied as a topical antiandrogen — it addresses DHT sensitivity at the follicle, the hormonal side. GHK-Cu is studied for collagen synthesis and general tissue repair — the environment the follicle sits in. Worth being straight about the gap: the collagen work is real and published, but there is no published study of GHK-Cu acting on hair follicles themselves, so the follicle half of that pairing is inference rather than evidence.
Researchers and formulators sometimes discuss combining a local antiandrogen with a tissue-support compound on the reasoning that a follicle needs both reduced androgen sensitivity and a healthy surrounding dermal environment to sustain growth. This page summarises the research behind each mechanism and why the pairing gets discussed — it is not a claim that the combination has been studied together in a dedicated clinical trial.
A non-steroidal topical antiandrogen, studied as a competitive androgen receptor antagonist acting locally at the scalp. Ex vivo scalp graft research and primate model studies have reported increased hair growth rates and follicle recycling with topical application, with no systemic hormonal effects detected in the primate research model. Full detail in the RU58841 Research Guide.
A naturally occurring copper-binding peptide studied for collagen synthesis, dermal papilla cell proliferation, and extension of the hair follicle's anagen (growth) phase in research models. Also separately studied for general skin repair and anti-inflammatory effects. Full detail in the GHK-Cu Research Guide.
| Compound | Research Model | Reported Effect |
|---|---|---|
| RU58841 | Human balding scalp grafts (nude mouse model) | Higher rate of follicles re-entering a second hair cycle; increased linear hair growth rate vs control. |
| RU58841 | Stump-tailed macaque model | Increased hair density, thickness, and length; no detected systemic effects. |
| GHK-Cu | Human hair follicle organ culture | Promoted hair shaft elongation and increased dermal papilla cell proliferation. |
⚠️ This combined rationale is a research discussion point, not evidence that the two compounds have been studied together in a dedicated trial. Treat this as a starting point for further reading, not a validated protocol.
Hair loss research is genuinely complex, and androgenetic alopecia has multiple contributing factors beyond DHT sensitivity and tissue health. Neither RU58841 nor GHK-Cu has completed large-scale human clinical trials for hair loss specifically. This guide exists to explain the mechanisms clearly, not to suggest either compound — alone or combined — is a guaranteed solution.
Note: AHK-Cu, a structurally related copper tripeptide sometimes discussed in the same hair-health context as this stack, is a different compound from GHK-Cu and is not part of the pairing covered on this page. See the separate AHK-Cu Research Guide for its own, considerably thinner, evidence base.
Reconstitution calculator, dosing-frequency planner and cycle-length calculator. No signup required.
Open the Peptide CalculatorsTracking food too? Free calorie counter with barcode scanner →